Discovery of human antibody specific to the spike glycoprotein subunit 2 of SARS-CoV-2 and characterization of its broad-spectrum neutralizing activity
Ying Chi, Huimin Yin, Chao Huang, Yiyue Ge, Jingxian Liu, Yuhan Ding, Fengjuan Shi, Zhou Cui, Shuo Ning, Yongjun Jiao, Lunbiao Cui · 2026
Read Discovery of human antibody specific to the spike glycoprotein subunit 2 of SARS-CoV-2 and characterization of its broad-spectrum neutralizing activity by Ying Chi, Huimin Yin, Chao Huang, Yiyue Ge, Jingxian Liu, Yuhan Ding, Fengjuan Shi, Zhou Cui, Shuo Ning, Yongjun Jiao, Lunbiao Cui (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13571484.txt.
Description
Chi and colleagues report a human antibody aimed at the coronavirus's most conserved part. Their 2026 paper screens for antibodies against the S2 subunit of the SARS-CoV-2 spike protein. Unlike the fast-mutating S1 region that most antibodies target, S2 changes little across variants, making it attractive for broad protection as the virus keeps evolving.
The team isolated an antibody specific to S2 and characterised its neutralising activity across viral variants. They report broad-spectrum neutralisation, supporting its potential as a therapeutic agent that frequent mutations are less likely to escape. The authors also frame the target as useful for diagnostic reagent development. More broadly, they present the S2-focused strategy as a template for vaccine and antibody design against other coronaviruses, not just the current pandemic virus.
Catalog record
| CREATOR | Ying Chi, Huimin Yin, Chao Huang, Yiyue Ge, Jingxian Liu, Yuhan Ding, Fengjuan Shi, Zhou Cui, Shuo Ning, Yongjun Jiao, Lunbiao Cui |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |